{"schema_version":"secwatch.filing_event.v1","accession":"0001846253-25-000053","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.118050+00:00","generated_at":"2026-05-22T05:29:02.753700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OmniAb Q1 2025 revenue $4.2M (+10% YoY), net loss $18.2M; lowers opex guidance","bullets":["Q1 revenue $4.2M (vs $3.8M in Q1 2024); net loss $18.2M ($0.17/share) vs $19.0M ($0.19/share) prior year.","Cash $43.6M at March 31, 2025; FY2025 revenue guidance reaffirmed $20-25M; opex guidance lowered to $85-90M from $90-95M.","Entered three new platform license agreements (Wyss, Takis, Orion); Orion deal includes $250K upfront and >$55M milestones.","Post-quarter asset sale to Angelini Pharma for Kv7.2 program: $3M upfront, >$170M milestones plus royalties.","Partner updates: Immunovant batoclimab positive MG/CIDP results; Teva Phase 2 celiac trial; Sugemalimab EMA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001846253-25-000053","json":"https://secwatch.observer/filing/0001846253-25-000053.json","markdown":"https://secwatch.observer/filing/0001846253-25-000053.md","text":"https://secwatch.observer/filing/0001846253-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/0001846253-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/oabi-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:29:02.753700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}